MFAR Clinical Research   Report issue

For profit Phase 2 Phase 3
Founded: Barcelona Spain (2006)

Organization Overview

First Clinical Trial
2018
NCT03623750
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

MFAR | MFAR Clinical Research | MFAR Clinical Research S.L.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Uveal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 12